Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
The net proceeds will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
Lead Product(s): AP‐PA02
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP‐PA02
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Armata Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 04, 2024
Details:
Xacduro (sulbactam & durlobactam), co-packaged for intravenous use, which act as beta-lactamase inhibitor, approved in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Xacduro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Xacduro (sulbactam for injection; durlobactam for injection), combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, approved for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Xacduro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
INO-3107 is clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases.
Lead Product(s): INO-3107
Therapeutic Area: Rare Diseases and Disorders Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
ETX2514 is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
ETX2514 or SUL-DUR is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Entasis Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
SUL-DUR is an IV, investigational drug that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV BLI, being developed for the treatment of infections caused by ABC, including carbapenem-resistant strains.
Lead Product(s): Sulbactam,Durlobactam,Imipenem
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Sulbactam-Durlobactam (SUL-DUR) is an IV, investigational drug that is combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, novel broad-spectrum IV BLI, developed for treatment of infections caused by ABC complex, including carbapenem-resistant strains.
Lead Product(s): Sulbactam,Durlobactam,Imipenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514sul
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022